Aldeyra Therapeutics Advances Reproxalap for Dry Eye with FDA NDA Acceptance and AbbVie Partnership

Aldeyra Therapeutics Advances Dry Eye Treatment with FDA Review Acceptance

Aldeyra Therapeutics, Inc. announces a significant milestone as the U.S. Food and Drug Administration (FDA) accepts its resubmitted New Drug Application (NDA) for reproxalap, an innovative investigational drug targeting the signs and symptoms of dry eye disease. This acceptance marks an important step in the therapeutic landscape for ocular health, particularly as dry eye disease affects millions of individuals and remains an area of unmet medical need. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for the review, scheduled for April 2, 2025, indicating the agency's commitment to evaluating reproxalap's potential benefits.

Reproxalap operates as a first-in-class small-molecule modulator of reactive aldehyde species (RASP), which play a role in inflammatory conditions. This mechanism positions reproxalap to potentially provide relief for patients suffering from both dry eye disease and allergic conjunctivitis, two prevalent issues within the ophthalmology market. Aldeyra's extensive clinical research, involving over 2,500 patients, supports the drug's safety profile, with the most commonly reported side effect being mild irritation at the site of administration. This strong foundation of clinical evidence enhances the likelihood of regulatory approval and subsequent market success.

In a strategic move to bolster its development efforts, Aldeyra expands its exclusive option agreement with AbbVie Inc. This agreement grants AbbVie the option to co-develop, manufacture, and commercialize reproxalap in the U.S. Should AbbVie choose to exercise this option, Aldeyra stands to receive a substantial upfront payment of $100 million, alongside potential milestone payments that could reach up to $300 million, contingent on FDA approval. The partnership also involves a shared profit model, with AbbVie receiving 60% and Aldeyra 40%, ensuring both companies are aligned in their commitment to bringing reproxalap to market.

In addition to the agreement's expansion, Aldeyra is poised to initiate pre-commercial activities, further underscoring its readiness for market entry. The funding for these activities will be shared, with AbbVie covering 60% and Aldeyra 40%. As AbbVie begins its own pre-commercial planning, this collaboration sets the stage for a comprehensive approach to the commercialization of reproxalap, potentially enhancing its market reach and effectiveness.

The acceptance of Aldeyra's NDA for reproxalap, combined with its strategic partnership with AbbVie, positions the company at the forefront of addressing significant challenges in ophthalmic care. As the FDA review date approaches, the industry watches closely to see how reproxalap may revolutionize treatment options for patients suffering from dry eye disease and related conditions.